Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.51 |
-0.4 |
0.11 |
21.57% |
2024-03-27 |
2023-12 |
-0.39 |
-0.5 |
-0.11 |
-28.21% |
2024-03-27 |
2023-12 |
-0.39 |
N/A |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.54 |
-0.48 |
0.06 |
11.11% |
2023-11-09 |
2023-09 |
-0.54 |
N/A |
N/A |
N/A |
2023-08-09 |
2023-06 |
-0.49 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-07-26 |
Scotiabank |
Upgrade |
|
Sector Outperform |
2023-03-15 |
JMP Securities |
Upgrade |
|
Outperform |
2022-11-10 |
JMP Securities |
Upgrade |
|
Market Outperform |
2022-07-18 |
JMP Securities |
Upgrade |
|
Market Outperform |
2021-11-22 |
SVB Leerink |
Upgrade |
|
Outperform |
2021-11-22 |
Cowen & Co. |
Upgrade |
|
Outperform |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-31 |
DE LOS PINOS ELISABET PH.D. |
Chief Executive Officer |
455.79K |
Stock Award(Grant) |
2023-01-18 |
DE ROSCH MARK PH.D. |
Chief Operating Officer |
58.64K |
Stock Award(Grant) |
2024-01-31 |
FEDER JULIE B |
Chief Financial Officer |
134.28K |
Stock Award(Grant) |
2024-01-31 |
HOPKINS JANET JILL |
Officer |
163.51K |
Stock Award(Grant) |
2023-11-07 |
JOHNSON DAVID MICHAEL |
Director |
0.00 |
Purchase |
2024-04-01 |
KILROY CONOR |
General Counsel |
96.00K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Matrix Capital Management |
5.36M |
66.23M |
14.04% |
2023-09-29 |
Medicxi Ventures Management (Jersey) Ltd |
3.04M |
27.27M |
7.96% |
2023-06-29 |
Eventide Asset Management LLC |
2.94M |
36.25M |
7.69% |
2023-06-29 |
Adage Capital Partners GP L.L.C. |
2.71M |
33.47M |
7.09% |
2023-06-29 |
Citadel Advisors Llc |
2.46M |
30.39M |
6.44% |
2023-06-29 |
Blackrock Inc. |
1.87M |
23.12M |
4.90% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund |
2.94M |
36.25M |
7.69% |
2023-08-30 |
iShares Russell 2000 ETF |
612.96K |
6.36M |
1.60% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
543.09K |
6.71M |
1.42% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
356.49K |
3.70M |
0.93% |
2023-06-29 |
Vanguard Extended Market Index Fund |
342.03K |
4.22M |
0.90% |
2023-08-30 |
iShares Russell 2000 Value ETF |
243.13K |
2.52M |
0.64% |